UPenn Algorithm Prioritizes Cancer Mutations for Immunotherapy

Article

The neoantigens found in the patients’ tumors (non-small-cell lung cancer) which were highly dissimilar were enriched for hydrophobic sequences, and correlated with survival rates after the PD-1 checkpoint therapy.

The promise of immunotherapy in fighting cancer is limited by finding the right targets for each patient. What works for one person’s biology is often useless in another’s.

Selecting the mutations using an algorithm could make the hunt for the right targets much easier, according to a new model created by a University of Pennsylvania team. The open-source tool called “antigen.garnish,” introduced in the journal Cell Systems, is now available online.

“We developed antigen quality analysis software, antigen.garnish, as an open-source tool to prioritize immunogenic neoantigens beyond predicted MHC (major histocompability complex) affinity alone for clinical use,” the authors wrote. “It is written in R to facilitate integration with Bioconductor and other toolsets for bioinformatics.”

“Our model works like a filter that highlights the signal and shows us which targets to focus on,” added lead author, Lee P. Richman, an M.D./Ph.D. candidate in Cancer Biology at the University of Pennsylvania’s Perelman School of Medicine, in a school statement on the work. 

Richman and co-authors Robert G. Vonderheide and Andrew J. Rech developed an analytic method to sort through neoantigens. 

Their model used five clinical datasets encompassing 318 total patients with cancer. 

The four quality metrics to assist the analysis included dissimilarity to the non-mutated proteome, which was predictive of the immunogenicity of the peptides. 

The neoantigens found in the patients’ tumors (non-small-cell lung cancer) which were highly dissimilar were enriched for hydrophobic sequences, and correlated with survival rates after the PD-1 checkpoint therapy, they wrote. 

The model thus targets the more dissimilar protein sequences because they may offer a better target, according to the authors. 

“With so many different possibilities of mutations, we essentially boiled the question of which targets to use down to a math problem, then developed an algorithm to solve it,” said Rech. “We also knew it was important to make this model available for other researchers to help inform vaccine development and clinical trials.”

antigen.garnishis human and murine input compatible and production pipeline ready: transparent, reproducible, fully documented, covered by unit tests, and employs continuous integration,” the authors concluded. 

 

The antigen.garnish tool is available here

Related Videos
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
© 2024 MJH Life Sciences

All rights reserved.